The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis
Abstract
In most patients with multiple sclerosis, the disease initiates with a first attack or clinically isolated syndrome. At this phase, magnetic resonance imaging is an important predictor of conversion to multiple sclerosis. With the exception of oligoclonal bands, the role of other biomarkers in patients with clinically isolated syndrome is controversial. In the present study, we aimed to identify proteins associated with conversion to multiple sclerosis in patients with clinically isolated syndrome. We applied a mass spectrometry-based proteomic approach (isobaric labelling) to previously collected pooled cerebrospinal fluid samples from patients with clinically isolated syndrome, who subsequently converted to clinically definite multiple sclerosis (n=30) and patients who remained as having clinically isolated syndrome (n=30). Next, three of the most represented differentially expressed proteins, i.e. ceruloplasmin, vitamin D-binding protein and chitinase 3-like 1 were selected for validation in individual cerebrospinal fluid samples by enzyme-linked immunosorbent assay. Only chitinase 3-like 1 was validated and cerebrospinal fluid levels were increased in patients who converted to clinically definite multiple sclerosis compared with patients who continued as clinically isolated syndrome (P=0.00002) and controls (P=0.012). High cerebrospinal fluid levels of chitinase 3-like 1 significantly correlated with the number of gadolinium enhancing lesions and the number of T2 lesions observed in brain magnetic resonance imaging scans performed at baseline, and were associated with disability progression during follow-up and shorter time to clinically definite multiple sclerosis (log-rank P-value=0.003). Cerebrospinal fluid chitinase 3-like 1 levels were also measured in a second validation clinically isolated syndrome cohort and found to be increased in patients who converted to multiple sclerosis compared with patients who remained as having clinically isolated syndrome (P=0.018). Our results indicate that patients who will convert to clinically definite multiple sclerosis could be distinguished from those patients who will remain as clinically isolated syndrome by proteomic analysis of cerebrospinal fluid samples. Although protein levels are also increased in other disorders characterized by chronic inflammation, chitinase 3-like 1 may serve as a prognostic biomarker for conversion to multiple sclerosis and development of disability which may help to improve the understanding of the aetiopathogenesis in the early stages of multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Barkhof, F. (1997) · Brain · doi:10.1093/brain/120.11.2059 · Cited by 1,251
Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
Brex, P. A., Ciccarelli, O., O'Riordan, J. I., Sailer, M., Thompson, A. J., & Miller, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011341 · Cited by 861
Protein labeling by iTRAQ: A new tool for quantitative mass spectrometry in proteome research
Wiese, S., Reidegeld, K. A., Meyer, H. E., & Warscheid, B. (2007) · PROTEOMICS · doi:10.1002/pmic.200600422 · Cited by 800
Berger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F., & Reindl, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022328 · Cited by 616
Wu, W. W., Wang, G., Baek, S. J., & Shen, R.-F. (2006) · Journal of Proteome Research · doi:10.1021/pr050405o · Cited by 576
Semaphorin 7A promotes axon outgrowth through integrins and MAPKs
Jeroen Pasterkamp, R., Peschon, J. J., Spriggs, M. K., & Kolodkin, A. L. (2003) · Nature · doi:10.1038/nature01790 · Cited by 515
A perspective on the use of iTRAQTM reagent technology for protein complex and profiling studies
Zieske, L. R. (2006) · Journal of Experimental Botany · doi:10.1093/jxb/erj168 · Cited by 468
Cited by
Miller, D. H., Chard, D. T., & Ciccarelli, O. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70274-5 · Cited by 507
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Rotstein, D., & Montalban, X. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0170-8 · Cited by 289
Self-citationYKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
Llorens, F., Thüne, K., Tahir, W., Kanata, E., Diaz-Lucena, D., Xanthopoulos, K., Kovatsi, E., Pleschka, C., Garcia-Esparcia, P., Schmitz, M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0226-4 · Cited by 249
Body fluid biomarkers in multiple sclerosis
Comabella, M., & Montalban, X. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70233-3 · Cited by 258
Self-citationThe utility of cerebrospinal fluid analysis in patients with multiple sclerosis
Stangel, M., Fredrikson, S., Meinl, E., Petzold, A., Stüve, O., & Tumani, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.41 · Cited by 229
Inflammation-related plasma and CSF biomarkers for multiple sclerosis
Huang, J., Khademi, M., Fugger, L., Lindhe, Ö., Novakova, L., Axelsson, M., Malmeström, C., Constantinescu, C., Lycke, J., Piehl, F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912839117 · Cited by 194
“In neuromyelitis optica, higher concentrations of eosinophils and various eotaxins were found in diseaseassociated lesions (8, 38, 39).”
BackgroundChitinase 3-like 1: prognostic biomarker in clinically isolated syndromes
Cantó, E., Tintoré, M., Villar, L. M., Costa, C., Nurtdinov, R., Álvarez-Cermeño, J. C., Arrambide, G., Reverter, F., Deisenhammer, F., Hegen, H., et al. (2015) · Brain · doi:10.1093/brain/awv017 · Cited by 193
Self-citationCerebrospinal fluid neurogranin and YKL ‐40 as biomarkers of Alzheimer's disease
Janelidze, S., Hertze, J., Zetterberg, H., Landqvist Waldö, M., Santillo, A., Blennow, K., & Hansson, O. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.266 · Cited by 179
Querol-Vilaseca, M., Colom-Cadena, M., Pegueroles, J., San Martín-Paniello, C., Clarimon, J., Belbin, O., Fortea, J., & Lleó, A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0893-7 · Cited by 158
Alirezaei, Z., Pourhanifeh, M. H., Borran, S., Nejati, M., Mirzaei, H., & Hamblin, M. R. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01698-3 · Cited by 142
Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis
Thompson, A. G., Gray, E., Thézénas, M., Charles, P. D., Evetts, S., Hu, M. T., Talbot, K., Fischer, R., Kessler, B. M., & Turner, M. R. (2018) · Annals of Neurology · doi:10.1002/ana.25143 · Cited by 130
Baldacci, F., Lista, S., Cavedo, E., Bonuccelli, U., & Hampel, H. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1304217 · Cited by 113
Hölttä, M., Minthon, L., Hansson, O., Holmén-Larsson, J., Pike, I., Ward, M., Kuhn, K., Rüetschi, U., Zetterberg, H., Blennow, K., et al. (2015) · Journal of Proteome Research · doi:10.1021/pr501076j · Cited by 100
Body fluid biomarkers for multiple sclerosis—the long road to clinical application
Teunissen, C. E., Malekzadeh, A., Leurs, C., Bridel, C., & Killestein, J. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.173 · Cited by 106
Teunissen, C. E., Elias, N., Koel‐Simmelink, M. J. A., Durieux‐Lu, S., Malekzadeh, A., Pham, T. V., Piersma, S. R., Beccari, T., Meeter, L. H. H., Dopper, E. G. P., et al. (2016) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.12.004 · Cited by 103
Clinically isolated syndromes and the relationship to multiple sclerosis
Brownlee, W. J., & Miller, D. H. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.02.026 · Cited by 84
Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls
Kroksveen, A. C., Guldbrandsen, A., Vedeler, C., Myhr, K. M., Opsahl, J. A., & Berven, F. S. (2012) · Acta Neurologica Scandinavica · doi:10.1111/ane.12029 · Cited by 80
Schilde, L. M., Kösters, S., Steinbach, S., Schork, K., Eisenacher, M., Galozzi, S., Turewicz, M., Barkovits, K., Mollenhauer, B., Marcus, K., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0206478 · Cited by 75
“8 [44, 45] [39] [44] P02766 TTR Transthyretin 10.”
InfluentialHuss, A. M., Halbgebauer, S., Öckl, P., Trebst, C., Spreer, A., Borisow, N., Harrer, A., Brecht, I., Balint, B., Stich, O., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8302-1 · Cited by 54
CHIT1 at Diagnosis Reflects Long‐Term Multiple Sclerosis Disease Activity
Oldoni, E., Smets, I., Mallants, K., Vandebergh, M., Van Horebeek, L., Poesen, K., Dupont, P., Dubois, B., & Goris, A. (2020) · Annals of Neurology · doi:10.1002/ana.25691 · Cited by 50
Mwale, P. F., Hsieh, C.-T., Yen, T.-L., Jan, J.-S., Taliyan, R., Yang, C.-H., & Yang, W.-B. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00801-8 · Cited by 47
Ten years of proteomics in multiple sclerosis
Farias, A. S., Pradella, F., Schmitt, A., Santos, L. M. B., & Martins‐de‐Souza, D. (2014) · PROTEOMICS · doi:10.1002/pmic.201300268 · Cited by 40
Chitinase 3-like 1 is neurotoxic in primary cultured neurons
Matute-Blanch, C., Calvo-Barreiro, L., Carballo-Carbajal, I., Gonzalo, R., Sanchez, A., Vila, M., Montalban, X., & Comabella, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-64093-2 · Cited by 38
Self-citationNovel CSF biomarkers to discriminate FTLD and its pathological subtypes
del Campo, M., Galimberti, D., Elias, N., Boonkamp, L., Pijnenburg, Y. A., van Swieten, J. C., Watts, K., Paciotti, S., Beccari, T., Hu, W., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.629 · Cited by 30
Chitinase Signature in the Plasticity of Neurodegenerative Diseases
Russo, C., Valle, M. S., Casabona, A., & Malaguarnera, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076301 · Cited by 29
Metadata
- Authors
- Comabella, M., Fernández, M., Martin, R., Rivera-Vallvé, S., Borrás, E., Chiva, C., Julià, E., Rovira, A., Cantó, E., Alvarez-Cermeño, J. C., Villar, L. M., Tintoré, M., & Montalban, X.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-03-17
- Volume
- 133
- Issue
- 4
- Pages
- 1082-1093
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2151454941
- Cited by
- 300
- References
- 45
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.